SG10202001117YA - Dioxolane analogues of uridine for the treatment of cancer - Google Patents

Dioxolane analogues of uridine for the treatment of cancer

Info

Publication number: SG10202001117YA
Authority: SG; Singapore
Prior art keywords: uridine; cancer; treatment; dioxolane; analogues
Prior art date: 2014-08-25

Application number

SG10202001117YA

Inventor

Richard Bethel

Anders Eneroth

Björn Klasson

Fredrik ÖBERG

Original Assignee

Medivir Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-08-25

Filing date

2015-08-24

Publication date

2020-04-29

2015-08-24 Application filed by Medivir Ab filed Critical Medivir Ab

2020-04-29 Publication of SG10202001117YA publication Critical patent/SG10202001117YA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

SG10202001117YA 2014-08-25 2015-08-24 Dioxolane analogues of uridine for the treatment of cancer SG10202001117YA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE1450983		2014-08-25
SE1550858		2015-06-22

Publications (1)

Publication Number	Publication Date
SG10202001117YA true SG10202001117YA (en)	2020-04-29

Family

ID=54014804

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10202001117YA SG10202001117YA (en)	2014-08-25	2015-08-24	Dioxolane analogues of uridine for the treatment of cancer
SG10201911558UA SG10201911558UA (en)	2014-08-25	2015-08-24	Dioxolane analogues of uridine for the treatment of cancer
SG11201701172SA SG11201701172SA (en)	2014-08-25	2015-08-24	Dioxolane analogues of uridine for the treatment of cancer

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SG10201911558UA SG10201911558UA (en)	2014-08-25	2015-08-24	Dioxolane analogues of uridine for the treatment of cancer
SG11201701172SA SG11201701172SA (en)	2014-08-25	2015-08-24	Dioxolane analogues of uridine for the treatment of cancer

Country Status (24)

Country	Link
US (7)	US10144750B2 (en)
EP (2)	EP3186244B1 (en)
JP (2)	JP6663424B2 (en)
KR (2)	KR102396905B1 (en)
CN (4)	CN110790789B (en)
AU (2)	AU2015308988C1 (en)
BR (1)	BR112017003898B1 (en)
CA (2)	CA2956251C (en)
CY (1)	CY1122945T1 (en)
DK (2)	DK3186244T3 (en)
EA (2)	EA031106B1 (en)
ES (2)	ES2796089T3 (en)
HR (1)	HRP20201023T1 (en)
HU (2)	HUE059640T2 (en)
IL (2)	IL250344B (en)
MX (1)	MX369649B (en)
MY (2)	MY188089A (en)
NZ (2)	NZ762628A (en)
PH (2)	PH12017500184B1 (en)
PL (2)	PL3186244T3 (en)
PT (2)	PT3186244T (en)
SG (3)	SG10202001117YA (en)
WO (1)	WO2016030335A1 (en)
ZA (1)	ZA201802864B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL3186244T3 (en) *	2014-08-25	2020-11-16	Medivir Aktiebolag	URIDINE DIOXOLATE ANALOGS IN THE TREATMENT OF CANCER
CN106543220A (en) *	2015-09-16	2017-03-29	博瑞生物医药（苏州）股份有限公司	Phosphoramidate compounds and preparation method thereof and crystal
WO2017098252A1 (en)	2015-12-11	2017-06-15	Nucana Biomed Limited	Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
PL3423061T3 (en)	2016-03-02	2024-12-16	Medivir Aktiebolag	COMBINATION THERAPY WITH SORAFENIB OR REGORAFENIB AND PHOSPHAMIDATE PRODRUG OF TROXACITABINE
CN106432328B (en) *	2016-09-14	2019-03-22	江苏福瑞生物医药有限公司	A kind of preparation method of Suo Feibuwei intermediate
EP3541824A1 (en) *	2016-11-18	2019-09-25	Neurovive Pharmaceutical AB	Liver prodrugs of mitochondrial proton ionophores
GB201709471D0 (en) *	2017-06-14	2017-07-26	Nucana Biomed Ltd	Diastereoselective synthesis of hosphate derivatives
JP7337539B2 (en) *	2018-06-21	2023-09-04	メディヴィル・アクチエボラーグ	Base-Modified Cytidine Nucleotides for Leukemia Therapy
WO2019245444A1 (en)	2018-06-21	2019-12-26	Medivir Ab	Base-modified cytidine nucleotides for leukemia therapy
EP3927347B1 (en) *	2019-02-18	2023-12-27	Medivir Aktiebolag	Drug combination for use in a method of treating liver cancer
CN110964057B (en) *	2019-12-25	2022-05-06	东南大学	Method for preparing sofosbuvir intermediate by using microfluid reaction device
CN113402546A (en) *	2020-03-17	2021-09-17	浙江四维医药科技有限公司	Dynamic kinetic resolution method for tail chain of Rudesiwei phosphate intermediate
CN115485029A (en) *	2020-04-15	2022-12-16	美迪维尔公司	MIV-818/lenvatinib combination therapy for liver cancer
CN113754692B (en) *	2020-06-03	2022-06-10	上海交通大学	Asymmetric catalytic synthesis of remdesivir intermediate (S,S)-phosphoramidate
CN114685558A (en) *	2020-12-28	2022-07-01	尚科生物医药（上海）有限公司	Preparation method of Reidesciclovir intermediate
CN114249764A (en) *	2021-11-10	2022-03-29	宁波大学	A kind of intermediate of phosphoramide ester prodrug and preparation method and application thereof
WO2025155547A1 (en) *	2024-01-17	2025-07-24	University Of Georgia Research Foundation, Inc.	An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5444063A (en) *	1990-12-05	1995-08-22	Emory University	Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6022876A (en) *	1996-11-15	2000-02-08	Yale University	L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
AU1201502A (en) *	2000-10-13	2002-04-22	Shire Biochem Inc	Dioxolane analogs for improved inter-cellular delivery
GB0317009D0 (en) *	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
WO2007106450A2 (en) *	2006-03-10	2007-09-20	University Of Georgia Research Foundation, Inc.	Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
WO2008030373A2 (en)	2006-09-01	2008-03-13	University Of Georgia Research Foundation, Inc.	L- oddc prodrugs for cancer
PL216525B1 (en)	2006-10-17	2014-04-30	Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk	5'-0-[(N-acyl) amidophosphate] - and 5'-0- [(N-acyl) amidothiophosphate]- and 5'-0- [N-acyl) amidodithiophosphate] and 5'-0- [N-acyl) amidoselenophosphate] - nucleosides and method for their manufacture
US20130143835A1 (en) *	2011-12-05	2013-06-06	Medivir Ab	HCV Polymerase Inhibitors
KR20160099090A (en) *	2013-11-27	2016-08-19	아이데닉스 파마슈티칼스 엘엘씨	Nucleotides for the treatment of liver cancer
PL3186244T3 (en) *	2014-08-25	2020-11-16	Medivir Aktiebolag	URIDINE DIOXOLATE ANALOGS IN THE TREATMENT OF CANCER

2015
- 2015-08-24 PL PL15756888T patent/PL3186244T3/en unknown
- 2015-08-24 CN CN201911148331.9A patent/CN110790789B/en active Active
- 2015-08-24 DK DK15756888.2T patent/DK3186244T3/en active
- 2015-08-24 CN CN201580056640.7A patent/CN107074826B/en active Active
- 2015-08-24 HR HRP20201023TT patent/HRP20201023T1/en unknown
- 2015-08-24 MY MYPI2017700615A patent/MY188089A/en unknown
- 2015-08-24 HU HUE19177824A patent/HUE059640T2/en unknown
- 2015-08-24 SG SG10202001117YA patent/SG10202001117YA/en unknown
- 2015-08-24 KR KR1020177008235A patent/KR102396905B1/en active Active
- 2015-08-24 CN CN202010199579.4A patent/CN111269264A/en active Pending
- 2015-08-24 PT PT157568882T patent/PT3186244T/en unknown
- 2015-08-24 PL PL19177824.0T patent/PL3572410T3/en unknown
- 2015-08-24 BR BR112017003898-6A patent/BR112017003898B1/en active IP Right Grant
- 2015-08-24 SG SG10201911558UA patent/SG10201911558UA/en unknown
- 2015-08-24 CA CA2956251A patent/CA2956251C/en active Active
- 2015-08-24 HU HUE15756888A patent/HUE050705T2/en unknown
- 2015-08-24 NZ NZ762628A patent/NZ762628A/en unknown
- 2015-08-24 DK DK19177824.0T patent/DK3572410T3/en active
- 2015-08-24 CN CN201911149251.5A patent/CN110804072B/en active Active
- 2015-08-24 EA EA201790328A patent/EA031106B1/en not_active IP Right Cessation
- 2015-08-24 MX MX2017002328A patent/MX369649B/en active IP Right Grant
- 2015-08-24 EP EP15756888.2A patent/EP3186244B1/en active Active
- 2015-08-24 WO PCT/EP2015/069370 patent/WO2016030335A1/en not_active Ceased
- 2015-08-24 NZ NZ729118A patent/NZ729118A/en unknown
- 2015-08-24 KR KR1020207008682A patent/KR102398714B1/en active Active
- 2015-08-24 US US15/506,692 patent/US10144750B2/en active Active
- 2015-08-24 EP EP19177824.0A patent/EP3572410B1/en active Active
- 2015-08-24 PT PT191778240T patent/PT3572410T/en unknown
- 2015-08-24 SG SG11201701172SA patent/SG11201701172SA/en unknown
- 2015-08-24 JP JP2017511226A patent/JP6663424B2/en active Active
- 2015-08-24 ES ES15756888T patent/ES2796089T3/en active Active
- 2015-08-24 AU AU2015308988A patent/AU2015308988C1/en active Active
- 2015-08-24 ES ES19177824T patent/ES2927212T3/en active Active
- 2015-08-24 CA CA3128645A patent/CA3128645C/en active Active
- 2015-08-24 EA EA201890648A patent/EA033300B1/en not_active IP Right Cessation
2017
- 2017-01-30 IL IL250344A patent/IL250344B/en active IP Right Grant
- 2017-01-31 PH PH12017500184A patent/PH12017500184B1/en unknown
- 2017-02-22 MY MYPI2021007010A patent/MY198325A/en unknown
2018
- 2018-03-20 AU AU2018201980A patent/AU2018201980B2/en active Active
- 2018-05-02 ZA ZA2018/02864A patent/ZA201802864B/en unknown
- 2018-12-03 US US16/208,083 patent/US10336780B2/en active Active
2019
- 2019-05-21 IL IL266766A patent/IL266766B/en active IP Right Grant
- 2019-07-01 US US16/459,165 patent/US10654877B2/en active Active
- 2019-08-19 PH PH12019501919A patent/PH12019501919A1/en unknown
2020
- 2020-02-14 JP JP2020023051A patent/JP6905609B2/en active Active
- 2020-04-13 US US16/847,477 patent/US10822360B2/en active Active
- 2020-05-22 CY CY20201100469T patent/CY1122945T1/en unknown
- 2020-11-02 US US17/087,483 patent/US11447511B2/en active Active
2022
- 2022-09-19 US US17/948,050 patent/US20230117570A1/en not_active Abandoned
2023
- 2023-05-31 US US18/326,992 patent/US20230382931A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2015308988A1 (en)	2017-02-23
SG10201911558UA (en)	2020-01-30
CA2956251C (en)	2022-10-25
JP2017526677A (en)	2017-09-14
EA201890648A2 (en)	2018-08-31
AU2015308988B2 (en)	2018-04-26
CN111269264A (en)	2020-06-12
IL250344A0 (en)	2017-03-30
KR102396905B1 (en)	2022-05-13
EA033300B1 (en)	2019-09-30
US20190100541A1 (en)	2019-04-04
PL3186244T3 (en)	2020-11-16
CN110790789A (en)	2020-02-14
CN110804072B (en)	2023-05-12
US20230382931A1 (en)	2023-11-30
CY1122945T1 (en)	2021-10-29
CN110804072A (en)	2020-02-18
CN107074826A (en)	2017-08-18
MY188089A (en)	2021-11-17
NZ729118A (en)	2022-02-25
IL266766A (en)	2019-07-31
HRP20201023T1 (en)	2020-10-16
US20170267705A1 (en)	2017-09-21
WO2016030335A1 (en)	2016-03-03
US10654877B2 (en)	2020-05-19
KR20170046736A (en)	2017-05-02
CA3128645A1 (en)	2016-03-03
AU2018201980A1 (en)	2018-04-12
HUE050705T2 (en)	2020-12-28
IL266766B (en)	2020-05-31
JP6663424B2 (en)	2020-03-11
ZA201802864B (en)	2019-07-31
NZ762628A (en)	2023-04-28
KR20200035482A (en)	2020-04-03
PH12017500184A1 (en)	2017-06-28
CA3128645C (en)	2023-06-27
BR112017003898A2 (en)	2017-12-05
PH12017500184B1 (en)	2017-06-28
JP6905609B2 (en)	2021-07-21
EP3186244B1 (en)	2020-04-22
AU2018201980B2 (en)	2019-05-16
US10336780B2 (en)	2019-07-02
EP3572410B1 (en)	2022-07-20
ES2927212T3 (en)	2022-11-03
MY198325A (en)	2023-08-24
KR102398714B1 (en)	2022-05-17
EP3186244A1 (en)	2017-07-05
US10822360B2 (en)	2020-11-03
PT3572410T (en)	2022-09-15
IL250344B (en)	2020-01-30
CN110790789B (en)	2023-05-12
MX369649B (en)	2019-11-15
ES2796089T3 (en)	2020-11-25
PH12019501919A1 (en)	2020-09-14
SG11201701172SA (en)	2017-03-30
US20190389890A1 (en)	2019-12-26
US20200239502A1 (en)	2020-07-30
DK3186244T3 (en)	2020-07-13
PL3572410T3 (en)	2022-10-03
BR112017003898B1 (en)	2022-10-18
EP3572410A1 (en)	2019-11-27
CN107074826B (en)	2020-05-22
CA2956251A1 (en)	2016-03-03
US20230117570A1 (en)	2023-04-20
US20210054008A1 (en)	2021-02-25
DK3572410T3 (en)	2022-08-29
EA031106B1 (en)	2018-11-30
MX2017002328A (en)	2017-05-22
EA201890648A3 (en)	2019-02-28
AU2015308988C1 (en)	2018-09-06
US10144750B2 (en)	2018-12-04
PT3186244T (en)	2020-05-29
JP2020090535A (en)	2020-06-11
HUE059640T2 (en)	2022-12-28
US11447511B2 (en)	2022-09-20
EA201790328A1 (en)	2017-08-31

Publication	Publication Date	Title
IL266766B (en)	2020-05-31	Dioxolane analogues of uridine for the treatment of cancer
ZA201704732B (en)	2019-02-27	Cyclic dinucleotides useful for the treatment of inter alia cancer
IL251560A0 (en)	2017-05-29	Methods for the preparation of ribosides
LT3122358T (en)	2021-04-12	Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
IL259996A (en)	2018-07-31	Combinations for the treatment of cancer
IL248767B (en)	2021-08-31	Trimethoxyphenyl-benzimidazole compound for use in the treatment of cancer
IL247859A0 (en)	2016-11-30	Cancer treatment
ZA201707024B (en)	2019-02-27	Cancer treatment composition
GB201408297D0 (en)	2014-06-25	Treatment of cancer
GB201409363D0 (en)	2014-07-09	Skin cancer treatment
GB201522433D0 (en)	2016-02-03	Cancer treatment
IL255167A0 (en)	2017-12-31	Compositions for the treatment of cancer
GB201417456D0 (en)	2014-11-19	Treatment of cancer
ZA201704589B (en)	2019-02-27	Compounds for the treatment of cancer
GB201512723D0 (en)	2015-08-26	Treatment of cancer
GB201507928D0 (en)	2015-06-24	Treatment of cancer
GB201504617D0 (en)	2015-05-06	Treatment of cancer
GB201409362D0 (en)	2014-07-09	Treatment of cancer
GB201405449D0 (en)	2014-05-07	Treatment of cancer
GB201405075D0 (en)	2014-05-07	Treatment of cancer
GB201411884D0 (en)	2014-08-20	Cancer therapy